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Abstract: Cancer is one of the greatest public health challenges. According to the World Health 8 
Organization (WHO) 9.6 million cancer deaths have been reported in 2018. The most common 9 
cancers include lung, breast, colorectal, prostate, skin cancer (non-melanoma) and stomach. The 10 
unbalance of physiological signalling pathways due to the acquisition of mutations in tumour cells 11 
is considered the most common cancer driver. The Wingless-related integration site (Wnt)/β-catenin 12 
pathway is crucial for tissue development and homeostasis in all animal species and its 13 
dysregulation is one of the most relevant events linked to cancer development and dissemination. 14 
The canonical and the non-canonical Wnt/β-catenin pathways are known to control both 15 
physiological and pathological processes including cancer. Herein the impact of the Wnt/β-catenin 16 
cascade in driving cancers from different origin has been examined. Finally, based on the impact of 17 
Extracellular Vesicles (EVs) on tumour growth, invasion and chemoresistance, and their role as 18 
tumour diagnostic and prognostic tools, an overview of the current knowledge linking EVs to the 19 
Wnt/β-catenin pathway is also discussed.  20 
Keywords: Wnt/β-catenin dependent pathway; Wnt/β-catenin independent pathway; colorectal 21 
cancer; breast cancer; ovarian cancer; extracellular vesicles 22 
 23 
Introduction 24 
The human wingless-related integration site (Wnt) genes encode 19 evolutionarily conserved 25 
glycoproteins with 22-24 Cys residues. In the endoplasmic reticulum (ER), the Wnt ligands are post-26 
translationally acetylated by porcupine, a membrane associated O-acyl transferase. Acetylation leads 27 
to palmitoylation which is required for the release and binding of Wnt to the frizzled (FZD) receptors. 28 
This, on turn, drives the biological response[1]. 29 
The Wnt signalling pathway regulates crucial cellular processes including cell fate 30 
determination, organogenesis during embryonic development, normal adult homeostasis, motility, 31 
polarity and stem cell renewal[2]. Moreover, its contribute in cancer has been extensively 32 
investigated[3]. 33 
The Wnt pathway has been widely studied and reviewed, and a general understanding of the 34 
transduction cascade has been clarified. The Wnt cascade has been subdivided into different branches 35 
due to its complexity[4,5]. They include the canonical Wnt/β-catenin (Wnt/β-catenin dependent 36 
pathway) and the non-canonical Wnt/β-catenin pathway (β-catenin-independent pathway). The 37 
latter was further allocated into two additional branches, the planar cell polarity (PCP) and the 38 
Wnt/calcium pathways[2]. Both of them contribute to cancer development and dissemination. 39 
The aim of the present review is to provide an overview of the current knowledge about the Wnt 40 
signalling pathway in tumour development and progression. Tumours from different origin are 41 
discussed. Although the canonical and the non-canonical Wnt/β-catenin pathway work together to 42 
control physiological and pathological processes[2], data related to each one are independently 43 
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debated. Finally, the contribute of extracellular vesicles (EVs) in triggering the Wnt/β-catenin cascade 44 
is also analyzed. 45 
Wnt canonical pathway: β-catenin dependent 46 
The canonical pathway turns around the β-catenin intracellular level (Figure 1). In the absence 47 
of Wnt proteins the β-catenin “destruction complex” keeps low β-catenin in the cell. The “destruction 48 
complex” mainly consists of two kinases: casein kinase 1α (CK1α), glycogen synthase kinase 3 β (GSK-49 
3β) and two scaffolds: axis inhibition (Axin), and adenomatous polyposis coli (APC). Firstly, β-catenin 50 
undergoes phosphorylation by CK1α at serine 45 (Ser45), Ser33, Ser37 and threonine 41 (Thr41) by 51 
GSK-3β. Then, the E3 ubiquitin ligase, denoted as β-transducin repeat–containing protein (βTrCP), 52 
marks β-catenin ubiquitination and degradation [1]. This prevents β-catenin nuclear translocation 53 
while allows histone deacetylation and chromatin compaction by the Groucho repressor, translating 54 
into the inhibition of gene transcription[6] (Figure 1a). 55 
 56 
Figure 1. The Canonical Wnt signalling pathway. (a) OFF STATE. In the absence of Wnt ligands β-57 
catenin moves to the “destruction complex” consisting of casein kinase 1α (CK1α), glycogen synthase 58 
kinase 3 β (GSK-3β) and two scaffolds: axis Inhibition (Axin), and adenomatous polyposis coli (APC). 59 
β-catenin undergoes phosphorylation at Ser45 residue by CK1α and at Ser33, Ser37 and Thr41 residues 60 
by GSK-3β. Then, the E3 ubiquitin ligase β-transducin repeat–containing protein (βTrCP), marks β-61 
catenin ubiquitination and proteasomal degradation. This prevents β-catenin nuclear accumulation 62 
while allows chromatin compaction and Groucho-mediated promoter repression. (b) ON STATE. 63 
The Wnt ligands bind to frizzled (FZD) receptor and the low-density-lipoprotein-related protein 5/6 64 
(LRP5/LRP6), this results in dishevelled (DVL) phosphorylation and β-catenin release from the 65 
“destruction complex”, allowing β-catenin accumulation and nuclear translocation. In the nucleus, 66 
the Groucho repressor undergoes displacement allowing β-catenin to interact with T-cell 67 
factor/lymphoid enhancer factor (TCF/LEF), chromatin remodeling and transcription of genes such as 68 
c-myc and cyclin D1. 69 
The activation of the canonical Wnt signal requires both the FZD family receptors and the low-70 
density-lipoprotein-related protein 5/6 (LRP5/LRP6) co-receptors which phosphorylation is essential 71 
for receptor activation. Wnt binding to its receptor results in dishevelled (DVL) phosphorylation, 72 
leading to Axin de-phosphorylation and decline of its cytoplasmic content [7]. Thereby, β-catenin can 73 
be released from the “destruction complex”, and its degradation prevented while stabilization 74 
allowed. Accumulation of β-catenin turns into its nuclear translocation [7]. 75 
Although several nuclear β-catenin binding partners have been involved in the control of gene 76 
transcription, the most relevant β-catenin partners are the members of the T-cell factor/lymphoid 77 
enhancer factor (TCF/LEF) family of transcription factors [7]. This complex binds to the promoter 78 
region of target genes and regulates their transcription.  79 
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Once in the nucleus, the engagement of β-catenin transiently converts the TCF/LEF into 80 
transcriptional activators which displace Groucho and induces chromatin remodelling and 81 
transcriptional activity (Figure 1b). 82 
A number of genes are targeted by Wnt-β-catenin. Among them, genes involved in positive- and 83 
negative-feedback regulation, cell-cycle progression, and stem cell homeostasis are the most 84 
commonly included genes. 85 
Wnt non-canonical pathways: Wnt/planar cell polarity (PCP) and Wnt/Calcium  86 
To date, the canonical Wnt/β-catenin pathway is much better characterized than the non-87 
canonical one (Figure 2).  88 
Figure 2. The Wnt non-canonical signalling pathways. (a) Wnt/planar cell polarity (PCP) pathway. Wnt 89 
ligands bind to FZD receptors and co-receptor RAR-related orphan receptor (ROR) and convey the signal 90 
to DVL. DVL forms the Disheveled associated activator of morphogenesis 1 (DVL-Daam-1) complex, which 91 
triggers RhoA, RHO and ROCK to control cytoskeletal rearrangement. On the other hand, DVL triggers 92 
RAC, JNK and AP-1 involved in cell motility and polarity. (b) Wnt/Calcium pathway. Wnt ligands bind to 93 
FZD and activate the phospholipase C (PLC), which hydrolyses the phosphatidylinositol (4,5)-94 
biphosphates (PIP2) to inositol (1,4,5)-triphosphates (IP3) and diacylglycerol (DAG). This translates into 95 
intracellular calcium release and the activation of CaN and CamKII. The calmodulin activation stimulates 96 
TAK-1 and NLK activity. CaN activates the NFAT, which moves to the nucleus and modulates the 97 
expression of genes involved in the control of gastrulation, ventral cell fate and tissue homeostasis. 98 
In the non-canonical PCP pathway, Wnt ligands bind to FZD receptors and co-receptor protein 99 
tyrosine kinase 7 (PTK7), RAR-related orphan receptor (ROR) or the receptor like tyrosine kinase 100 
(RYK) and convey the signal to DVL. On the one side, DVL forms the disheveled associated activator 101 
of morphogenesis 1 (DVL-Daam-1) complex, which triggers a small guanosine-5'-triphosphate (GTP) 102 
GTPase, such as ras homolog gene family member A (RhoA), RHO and RHO-associated kinase 103 
(ROCK). DVL also triggers ras-related C3 botulinum toxin substrate (RAC), JUN-N-terminal kinase 104 
(JNK) and the activator protein-1 (AP-1).[7] The PCP pathway is involved in the cytoskeletal 105 
rearrangement, cell motility and co-ordinates cell polarity. In vertebrates, the PCP pathway is also 106 
required for morphology and migration of dorsal mesodermal cells undergoing gastrulation, hair 107 
follicle organization, and orientation of stereocilia in the sensory epithelium of the inner ear [8] 108 
(Figure 2a). 109 
In the calcium-dependent pathway Wnt ligands bind to FZD and activate the phospholipase C 110 
(PLC) which hydrolyses the phosphatidylinositol (4,5)-biphosphates (PIP2) to inositol (1,4,5)-111 
triphosphates (IP3) and diacylglycerol (DAG). This translates into the release of the intracellular 112 
calcium and the activation of both calcineurin (CaN) and calcium/calmodulin-dependent kinase II 113 
(CamKII). Moreover, the activation of calmodulin promotes the activation of the TGF-β-Activated 114 
kinase 1 (TAK-1) and nemo-like kinase (NLK), thereby antagonizing and neutralizing the canonical 115 
Wnt/β-catenin cascade. CaN activates the nuclear factor of activated T-cells (NFAT), which moves to 116 
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the nucleus and regulates the expression of target genes [7] (Figure 2b). The calcium-dependent 117 
pathway plays a crucial role in several processes, including early pattern formation during 118 
gastrulation [2], ventral cell fate [9], dorsal axis formation [10], and tissue homeostasis [11]. 119 
COLORECTAL CANCER 120 
Colorectal cancer (CRC) is one of most common cancer worldwide and represents a deep cause 121 
of cancer mortality [12] with a rapid increase in incidence and death rate [13]. Dienstmann et al. [14] 122 
established a new classification of CRCs into four consensus molecular subtypes (CMSs). Among 123 
them CMS2, CMS3, and CMS4 have a higher rate of APC mutations (over 50%) compared to CMS1. 124 
Each CMS has unique features: CMS1 (MSI Immune, 14%): hyper- mutated, microsatellite instability, 125 
strong immune activation; CMS2 (Canonical, 37%): epithelial, chromosomally unstable, marked Wnt 126 
and myc signalling activation; CMS3 (Metabolic, 13%): epithelial, metabolic dysregulation; and CMS4 127 
(Mesenchymal, 23%): a prominent transforming growth factor β (TGFβ) activation, stromal invasion, 128 
and angiogenesis. Samples with combined features (13%) represent transition phenotypes or are 129 
supposed to reflect the intra-tumour heterogeneity [14]. 130 
The heterogeneous genetic ground underlying CRC initiation and progression mainly involves 131 
gene fusion, deletion or amplification, somatic gene mutations and epigenetic alterations. Wnt/β-132 
catenin signalling has emerged as one of the most significant biological pathways in both 133 
physiological setting and CRC development. Almost all CRC are characterized by a hyper-active 134 
Wnt/β-catenin pathway, which, in many cases, is considered the most critical cancer initiating and 135 
driving event. Proteins and miRNAs guiding the Wnt/β-catenin pathway and proposed as potential 136 
CRC therapeutic targets are discussed. 137 
Canonical Wnt/β-catenin pathway and CRC 138 
Ring finger protein 6 (RNF6) is an oncogene frequently upregulated by gene amplification in 139 
primary CRC. Moreover, APC mutation and RNF6 copy number amplification were commonly found 140 
in CRC patients. RNF6 is a RING-domain E3 ubiquitin ligase and exerts its pro-metastatic effects by 141 
promoting CRC cell growth, cell-cycle progression, and epithelial to mesenchymal transition (EMT). 142 
Furthermore, RNF6 expression and its gene amplification have been considered independent 143 
patients‘ prognostic factors. RNF6 mediates the polyubiquitination of the transducin-like enhancer of 144 
split 3 (TLE3), a transcriptional repressor of the β-catenin/TCF4 complex, and its proteasome 145 
degradation. The lack of TLE3/TCF4/LEF interaction enhances the Wnt/β-catenin transcriptional 146 
activity, and the expression of its downstream target genes [15] (Table 1). 147 







IMPACT ON TUMOUR  REF. 
RNF6 CRC Upregulated β-catenin cell growth 




LGR5 CRC, BC Upregulated β-catenin proliferation 
migration 
[16,6568] 
TNIK Gastric Upregulated β-catenin cell growth [19,20] 
KYA1797K CRC Upregulated β-catenin tumour growth 
stem cell features 
[1922] 
























SLC35C1 CRC Downregulated β-catenin cell proliferation 
cell progression 
[32][35] 




KLHL22 CRC Downregulated β-catenin invasion 
migration 
[37][40] 
CCL2 CRC Upregulated Non-canonical progression [45][48] 





ST7L BC Downregulated GSK-3β proliferation 
invasion 
[67][69] 




















Nek2B TNBC Upregulated β-catenin chemoresistance [89][91] 
VANGL2 TNBC Upregulated p62/SQSTM1 (PCP) migration 
anchorage-dependent 
and independent cell 
proliferation 
[90][92] 
HePTP TNBC Upregulated -GSK-3β metastasis [91][93] 
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β-catenin 





DKK1 OC Downregulated β-catenin stemness [100][102] 
SFRP1 OC Downregulated β-catenin cell growth 
stem-like phenotype 
[101][103] 
AXIN2 OC Downregulated β-catenin stem-like phenotype [101][103] 









FZD7 OC Upregulated Non-canonical EMT 
cell cycle progression 
migration 
[109][112] 
ITGBL1 OC Upregulated Non-canonical migration 
adhesion 
[110][113] 




VDR Melanoma Upregulated β-catenin tumour growth 
immune response 
[119][122] 
EVs CRC Upregulated     β-catenin - migration, 
- metastasis 
- tumour growth 
[123] 










Upregulated     β-catenin 
    GSK-3β 




EVs CRC Upregulated β-catenin - dedifferentiation 
- drug resistance 
- colony formation 
[127,128] 
EVs HCC Silenced β-catenin - proliferation 
- tumour growth 
[132,133] 
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EVs OSCC Upregulated β-catenin - metastasis 
- stemness 
- cell reprogramming 
- chemoresistance 
[136] 









EVs BC Upregulated Wnt-PCP - cell growth and 
motility 
[139] 
The leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is a Wnt/β-catenin target 149 
gene implicated in cancer cell proliferation and migration. It has been reported that LGR5 is highly 150 
expressed in CRC tissues compared to the healthy ones. A decline in β-catenin and c-myc mRNA 151 
expression were detected by knocking-down LGR5 expression, suggesting that it may regulate the 152 
Wnt/β-catenin activity by modulating the expression of β-catenin. Furthermore, since targeting LGR5 153 
improves the response to chemotherapy, LGR5 has been proposed as a novel therapeutic target in 154 
CRC [16] (Table 1). 155 
The β-catenin and RAS signalling pathways are frequently associated to the development and 156 
progression of several different cancers. They mainly act on cancer stem cell (CSC) expansion. High 157 
levels of β-catenin and RAS proteins are considered the major drivers of CSC expansion and cancer 158 
dissemination and are associated with poor patient’s outcome [17].  159 
Targeting the CSC pool without affecting the somatic stem cell (SSC) niche is one of the major 160 
goals of the last decades. As reported by Lenz et al. [18], the β-catenin antagonist molecule, ICG-001, 161 
effectively prevented the interplay between β-catenin and its coactivator cAMP response element 162 
binding protein (CREB)-binding protein (CBP). Moreover, ICG-001 effectively and without side 163 
effects abrogated drug-resistant cells. On the same line, PRI-724, a second generation of CBP/β-164 
catenin antagonist, was found safe in pre-clinical studies and displayed an acceptable toxicity profile. 165 
Yu et al. [19] investigated the traf2- and nck-interacting kinase (TNIK) amplification and its role 166 
in tumor progression by applying siRNA technology, while Masuda et al. [20] have generated a small 167 
molecule denoted as NCB-0846 acting as TNIK inhibitor. TNIK selectively binds both to TCF4 and β-168 
catenin in order to promote cancer cell growth via Wnt/β-catenin cascade and drives colorectal CSC 169 
expansion. The NCB-0846 inhibitor was effective in interfering with TNIK activity tumour growth.  170 
KYA1797K, a small molecule identified by Cha et al. [21], was found effective in suppressing 171 
CRC growth due to the activation of GSK-3β via Axin binding and β-catenin/RAS destabilization. In 172 
line with this observation, treatment with KYA1797K abrogated CRC stem cell features both in vitro 173 
and in vivo. Mechanistically, KYA1797K pushes β-catenin and RAS towards the Axin binding [22] 174 
(Table 1). 175 
In the last decade miRNAs have gained particular attention in cancer [23]. miRNA profiling has 176 
been linked to cancer types, stage, and invasion [24]. Moreover, oncogenic or tumour suppressive 177 
actions have been linked to miRNA expression. For these reasons, miRNAs are considered valuable 178 
tools for cancer diagnosis and prognosis and therefore useful therapeutic targets (Table 2).  179 








miR-144-3p CRC Downregulated cell proliferation [22][25-27] 
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miR106a BC Upregulated cell growth 
cisplatin sensitivity 
[58][61] 
















miR-27a-3p BC Upregulated proliferation 
migration. 
[93][96] 
miR-1207 OC Upregulated tumorigenicity 
stem cell-like traits 
stemness 
[100][103] 




miR-1180 OC Upregulated cell proliferation 
glycolysis 
[103][106] 
miR-939 PCa Downregulated tumour stage 
metastasis 
[116][120] 
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miR-1260b LAC EVs Upregulation cell invasion 
metastasis 
[137][136] 
miR-214-3p TEC EVs Upregulation neovessel formation [139][139] 
miR-24-3p TEC EVs Downregulation neovessel formation [139][139] 
Sun and co-workers [25] identified miR-144-3p as a new biomarker for CRC diagnosis and 181 
response to treatment. miR-144-3p was found downregulated and associated with CRC pathological 182 
stages in CRC patients. Interestingly, miR-144-3p overexpression reduced CRC cell proliferation by 183 
delaying G1/S phase transition in tumour cells. On the contrary, the B-cell lymphoma 6 protein 184 
(BCL6), a nuclear protein belonging to the BTB/POZ/zinc finger (ZF) family of transcription factors, 185 
was found upregulated and surprisingly post-transcriptionally regulated by miR-144-3p. Previous 186 
studies revealed that BCL6 is involved in the control of cell cycle progression and differentiation 187 
[26,27]. Indeed, miR-144-3p/BCL6 co-operate to inhibit cellular proliferation, development, and 188 
progression of CRC by interfering with c-myc and cyclin D1 expression [25] (Table 1). 189 
miR-377-3p displays an ambiguous role in CRC. Liu and colleagues [28] uncovered that 190 
upregulation of miR-377-3p promotes G1-S phase transition, cell expansion and EMT, while represses 191 
apoptosis in CRC patients. Moreover, GSK-3β, a direct miR-377-3p target, was found upregulated 192 
upon miR-377-3p overexpression. These data suggest that a complex regulatory network boosting 193 
tumour progression is associated with the expression of miR-377-3p in CRC.  194 
Conversely, in a recent study, Huang et al. [29] have shown that miR-377-3p, significantly 195 
reduced in CRC patients, is involved in the control of proliferation, migration and chemo resistance, 196 
particularly at advanced tumour stage. The authors investigated miR-377 functions and mechanism 197 
of action in CRC cells. The zinc finger E-box binding homeobox 2 (ZEB2) and the X-linked inhibitor 198 
of apoptosis protein (XIAP) are two positive regulators of the Wnt/β-catenin cascade [30,31]. In CRC, 199 
ZEB2 enables tumour progression and invasion, whereas XIAP promotes cell proliferation and 200 
chemoresistance. De facto, miR-377-3p overexpression was found to suppress the malignant CRC 201 
phenotype, as well as cell proliferation, invasion and drug resistance by directly targeting the 3’ UTR 202 
sequence of both ZEB2 and XIAP mRNAs. Since miR-377-3p/ZEB2-XIAP inhibited CRC progression 203 
by reducing Wnt/β-catenin-associated gene expression (e.i. cyclin D1, Axin2, TCF1, SOX2, c-myc, 204 
matrix metalloproteinase-2 (MMP-2), MMP-9, CD44, vascular endothelial growth factor (VEGF), and 205 
Twist) approaches increasing its expression have been proposed for novel therapeutic options (Table 206 
1). 207 
Functional experiments showed that miR-520e plays a pivotal role in regulating CRC cell 208 
proliferation, colony formation and invasion [32]. Moreover, it has been reported that low miR‐520e 209 
expression is associated with the increased CRC growth and migration. The astrocyte elevated gene‐210 
1 (AEG‐1), which acts as an oncogene [33], is a direct miR-520e target in CRC. Cells overexpressing 211 
miR-520e displayed lower GSK-3β phosphorylation and β-catenin expression. Mechanistically, it was 212 
found that miR-520e regulates cancer cell behaviour by targeting AEG‐1 which on turn inactivate the 213 
Wnt/β-catenin signalling and the transcription of its downstream genes. Hence, miR‐520e 214 
overexpression could represent a promising therapeutic target in CRC by AEG‐1 suppression. 215 
Approximately 40–50% of CRC patients develop metastasis, mostly to the liver and lung. In 216 
cancer patients, metastases are associated with 90% of all cancer-related death, thereby the 217 
mechanisms accounting for the metastatic spread have been deeply investigated. Zhang et al. [34] 218 
demonstrated that the rhomboid domain containing 1 (RHBDD1) plays a crucial role in driving 219 
metastasis formation in CRC patients, via the Wnt/β-catenin pathway. It has been shown that 220 
RHBDD1 is able to influence the Wnt/β-catenin cascade by increasing the phosphorylation of β-221 
catenin at the Ser552 and Ser675 residue without affecting its nuclear translocation. Moreover, it 222 
promotes EMT, stemness, migration and invasiveness. RHBDD1 also improves the expression of the 223 
β-catenin target gene, ZEB1. Furthermore, the protein level of RHBDD1 positively correlated with 224 
ZEB1. Thereby, RHBDD1 has been proposed as a novel therapeutic target and/or a clinically useful 225 
biomarker for metastatic CRC (Table 1). 226 
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 10 of 30 
 
SLC35C1, or GDP-fucose transporter 1, is a member of the solute carrier (SLC) superfamily of 227 
solute carriers. The Deng’s group [35] explored the mechanism throughout SLC35C1 regulates the 228 
canonical Wnt/β-catenin pathway in CRC. They demonstrated a reduction of SLC35C1 and an 229 
increase of β-catenin at all tumour stages. Indeed, silencing SLC35C1 resulted in the increased release 230 
of Wnt3a and c-myc, Axin2 and cyclin-D1 expression. This suggests that SLC35C1 is involved in the 231 
control of the canonical Wnt/β-catenin pathway, and thereby in tumour cell proliferation and tumour 232 
progression (Table 1).  233 
Neuronal pentraxin 2 (NPTX2) is a member of the neuronal pentraxin family and is essential for 234 
the formation of synapsis. NPTX2 was found overexpressed at both mRNA and protein level in CRC, 235 
particularly in metastatic lesions [36]. NPTX2, which was found to positively correlate with tumour 236 
stages, lymphatic invasion, distant metastasis, and poor patients’ outcome, promotes β-catenin 237 
nuclear translocation and the expression of c-myc, cyclin D1, Snail, and N-cadherin. No NPTX2 238 
receptors have been identified in CRC, however, its cellular internalization was found mediated by 239 
the Wnt/β-catenin receptor, FZD6. Additionally, it has been reported that NPTX2/FZD6 interaction 240 
translates in cancer cell proliferation and metastasis formation by triggering the Wnt/β-catenin 241 
pathway [36] (Table 1). 242 
Aberrant gene expression and DNA methylation profiles are considered hallmarks of CRC 243 
initiation and progression [37]. Due to the APC inactivating mutations, the Wnt/β-catenin pathway 244 
plays a key role in CRC metastatic spread [35][38]. Bruschi el al. [39] investigated the early 245 
transcriptional and epigenetic changes resulting from APC inactivation in intestinal crypts in crypt 246 
base columnar (CBC) cells. The authors have found that APC disruption rapidly induces changes in 247 
DNA methylation, indicating that focal remodelling of the DNA methylation profile occurs early and 248 
concomitantly with the first oncogenic event. Moreover, it has been demonstrated that the hyper-249 
activation of the Wnt/β-catenin pathway associated with the APC loss-of-function turns out in a rapid 250 
increase of intestinal stem cell commitment towards differentiation. Again, it was correlated with the 251 
remodelling of the DNA methylation profile. This study unveils that early changes in DNA 252 
methylation are crucial for the impaired fate decision program associated with APC loss-of-function. 253 
The kelch-like family member 22 (KLHL22) is a tumour suppressor protein involved in the 254 
development/progression of several cancers [40]. Low expression of KLHL22 was found in CRC 255 
tissues. KLHL22 overexpression was associated with decreased migration, invasion and reduced 256 
expression of the EMT markers, vimentin, N-cadherin, Twist1 and Snail1. Intriguingly, KLHL22 257 
knockdown led to β-catenin and LEF increased expression, while KLHL22 overexpression translates 258 
into GSK-3β upregulation and β-catenin downregulation [40] (Table 1). 259 
Non-canonical Wnt pathway and CRC 260 
The canonical and non-canonical Wnt family members play discrete roles in CRC. The activation 261 
of the Wnt/calcium pathway turns into stimulation of sensitive proteins such as CamKII and PKC 262 
[38][41]. A Ror family of receptor tyrosine kinases, the ROR2 has been shown to act as a Wnt5a 263 
receptor or co-receptor [42]. Wnt5a has different roles in CRC. It can act as antagonist or agonist of 264 
the canonical Wnt/β-catenin pathway, depending on the cellular context. Lee et al. [43] noticed that 265 
the antagonism between the canonical and the non-canonical Wnt/β-catenin signalling pathways is 266 
linked to Wnt5a. Mechanistically, Wnt5a suppressed the canonical Wnt/β-catenin cascade by acting 267 
as ligand on the RORα [42]. After PKCα-mediated phosphorylation, RORα modifies its affinity and 268 
interacts with the armadillo repeat domains of β-catenin, thus supressing its transcriptional activity. 269 
Three relevant goals have been recently achieved by Voloshanenko et al. [44] supporting the role 270 
of Wnt5a/b in cell growth, via the non-canonical β-catenin pathway. First, they identified the 271 
procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2), the hydroxyacyl-CoA dehydrogenase 272 
(HADH), ligand-dependent corepressor (LCOR) and the receptor expression-enhancing protein 1 273 
(REEP1) as candidate genes regulated by the non-canonical Wnt/β-catenin pathway. Second, these 274 
genes were found regulated by Wnt5a/b, as well as by ROR2, the DVL2, the activating transcription 275 
factor 2 (ATF2) and ATF4 in a non-canonical Wnt/β-catenin independent manner. Lastly, Wnt5a/b 276 
silencing was found to impair cancer cell proliferation. 277 
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Among several soluble Wnt proteins, Wnt11 was found upregulated in CRC patients [45]. 278 
Recently, Gorroño-Etxebarria and colleagues [46] have shown that increased Wnt11 and its FZD6, 279 
RYK, PTK7 receptors, positively correlate with poor prognosis. Additionally, Wnt11 downregulated 280 
β-catenin transcriptional activity and increased ATF2 via the non-canonical Wnt signalling pathway. 281 
Thereby, Wnt11 has been proposed as a prognostic biomarker and therapeutic target in CRC patients. 282 
Tumour micro environment (TME) has a pivotal role in cancer development [47]. Liu et al.[48] 283 
reported that, unlike CRC cells, tumour associate macrophages (TAMs), and in particular M2-like 284 
cells express Wnt5a. Furthermore, it has been shown that Wnt5a positive TAMs regulate 285 
macrophages infiltration, tumour cell proliferation and migration. Wnt5a pro-tumour activity was 286 
found associated with the overexpression of the C-C motif chemokine ligand 2 (CCL2) in Wnt5a-287 
treated macrophages. Consistently, Wnt5a knockdown reduced CCL2 expression in TAMs and their 288 
cancer-promoting activity. In Wnt5a-treated macrophages both CaMKII and ERK1/2 undergo 289 
phosphorylation and lead to CCL2 secretion. This study provided evidence for a new role of Wnt5a 290 
in CRC and describes a potential novel therapeutic target (Table 1). 291 
BREAST CANCER 292 
Breast cancer (BC) is the most diagnosed cancer in women [46][49], the first cause of cancer death 293 
in women worldwide [47][50], and one of the most expensive health care cost [46][49]. Both the 294 
canonical and non-canonical Wnt/β-catenin pathways are essential for mammary gland development 295 
[51] and for BC growth and dissemination [52]. Hyper-active Wnt/β-catenin was reported in breast 296 
tumours [50][53]. In human BC, elevated intracellular β-catenin level has been associated with high 297 
tumour grade [54] and poor prognosis. Moreover, up to 90% of metaplastic carcinomas and non-298 
metastasizing fibromatosis have been associated with the highest β-catenin expression level [55]. 299 
Moreover, proteins such as Wnt3a [56] and xenopus frizzled 7 (Xfz7) [57] have been involved in the 300 
activation of both the canonical and the non-canonical Wnt signalling pathways.  301 
Canonical Wnt pathway and BC 302 
Dysregulation of the Wnt/β-catenin cascade has been associated with cancer initiation and 303 
metastasis formation [56][58]. Moreover, high β-catenin expression has been reported in basal-like 304 
BC subtype [50][53]. Additionally, it has been demonstrated that loss of secreted frizzled-related 305 
protein 1 (sFRP1) is an early event in BC patients and is associated with poor prognosis [59]. 306 
Furthermore, the activation of the Wnt/β-catenin cascade has been associated with radio resistance 307 
of progenitor cells. Thereby, the Wnt/β-catenin pathway has been proposed as a target to harm the 308 
self-renewal potential of stem/progenitors [60].  309 
A recent study demonstrated that high β-catenin level is associated with miR106a 310 
overexpression and involved in BC cell growth. Additionally, high level of miR106a was reported to 311 
reduce cisplatin sensitivity. Major results were obtained exploiting the Wnt inhibitor, FH535. In fact, 312 
FH535 treatment reduced the expression of β-catenin, cyclin D1, c-myc and Ki67, impaired tumour 313 
growth and induced apoptosis [61]. 314 
In a different study [62], the impact of the Wnt/β-catenin canonical pathway in cisplatin 315 
resistance was investigated by silencing β-catenin via small interfering RNA (siRNA). The authors 316 
demonstrated that upon β-catenin silencing, the cells become more sensitive to cisplatin treatment. 317 
These effects were associated with the increased expression of the apoptotic proteins caspase 3/9.  318 
A recent study demonstrated that miR-5188, aberrantly expressed in breast cancer patients, 319 
positively correlates with poor prognosis. The molecular analyses revealed that miR-5188 directly 320 
targets the forkhead box protein O1 (FOXO1). In physiological setting, FOXO1 binds β-catenin and 321 
induces its degradation. This implies that miR-5188 overexpression leads to β-catenin nuclear 322 
accumulation and transcription of its downstream target genes, mainly involved in EMT, tumour cell 323 
proliferation, metastasis formation and chemo resistance. Moreover, the authors elegantly showed 324 
that miR-5188 expression is under the control of c-Jun, which directly binds to its promoter region. 325 
This on turn generates a positive loop accelerating tumour progression. Clinically, miR-5188 has been 326 
proposed as a diagnostic or prognostic factor and/or a direct target for anti-cancer therapy [63]. 327 
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The upregulation of the lncRNA hoxa transcript at the distal tip (HOTTIP) has been also linked 328 
to poor prognosis in BC patients. Overexpression of HOTTIP correlates with the expansion of breast 329 
CSCs (BCSCs) and the expression of the stem cell markers, OCT4 and SOX2. Han et al. [64] 330 
demonstrated a reduced expression of differentiation markers, such as CK18 and CK14 and that miR-331 
148a inhibits BC cell migration and invasion by directly targeting Wnt1. Moreover, it has been 332 
reported that HOTTIP controls miR-148a-3p by acting as a competing endogenous RNA (ceRNA). 333 
Thereby, HOTTIP promotes expansion of CSCs in vitro and tumorigenesis in vivo by regulating the 334 
miR-148a-3p/Wnt1/β-catenin axis [64]. These data are summarized in Table 2. 335 
The LGR4 was identified as a prognostic marker in breast tumours displaying poor prognosis 336 
[65]. A tight molecular interplay between LGR4 and Wnt/β-catenin signalling has been reported to 337 
control stemness. Indeed, LGR4 binding to the soluble R-spondin proteins eases the Wnt/β-catenin 338 
cascade [64][66]. Previous studies have proven that upregulation of ZEB1 by SLUG (the protein 339 
product of SNAI2), increased EMT [67]. As a matter of fact, LGR4 knockdown leads to SLUG and 340 
ZEB1 downregulation, thereby impairs invasion and metastasis [68]. A correlation with poor 341 
outcome and the expression of the LGR4 homolog LGR5 was also reported. LGR5 maintains the pool 342 
of BCSCs and promotes tumour progression and invasiveness by activating the Wnt/β-catenin 343 
canonical pathway [68] (Table 1). 344 
Wang et al. [69] first demonstrated that the expression of the suppression of tumorigenicity 7 345 
like (ST7L) is downregulated in BC cells, and more importantly, that ST7L acts as an antitumor 346 
supervisor by reducing GSK-3β phosphorylation and inducing β-catenin degradation. However, the 347 
mechanisms through which ST7L controls GSK-3β phosphorylation is still missing (Table 1). 348 
A recent study [70] reported the overexpression of the transmembrane emp24 domain (TMED) 349 
in BC and its correlation to poor prognosis. Aberrant level of TMED boosts cell cycle progression, 350 
colony formation, migration and invasion and the expression of CDK2, CDK4, CDK6, cyclin E, β-351 
catenin, cyclin D1, c-myc, MMP-7 and TCF4. Conversely, silencing TMED3 drastically reduced 352 
migration and invasion. Moreover, the observation that β-catenin knockdown translates in the 353 
reduction of its regulated genes supports the notion that the oncogenic effect of TMED goes through 354 
the Wnt/β-catenin pathway (Table 1). 355 
Cryptotanshinone (CTS) is an herbal medicine derived from roots of salvia miltiorrhiza which 356 
displays anti-tumour properties. It has been shown that in vitro CTS reduces tumour cell growth, 357 
migration and invasion by downregulating the pyruvate kinase muscle isozyme M2 (PKM2), a 358 
protein involved in glycolysis, and more importantly in β-catenin activation [71]. 359 
Wnt non-canonical pathway and BC 360 
Among the Wnt ligands, the most extensively studied ligand, activating the β-catenin 361 
independent pathway, is Wnt5a. However, its different biological actions are enlightened by the 362 
observation that it can also initiate the canonical β-catenin signalling cascade [70][72]. 363 
Wnt5a is an evolutionarily conserved Wnt ligand, which plays an important role in 364 
developmental processes. Wnt5a-/- knockout mice showed perinatal lethality, due to developmental 365 
defects [73]. 366 
In tumorigenesis, Wnt5a signalling is central and displays multiple intriguing and opposite roles 367 
mainly acting as a β-catenin antagonist. These data are discussed. 368 
The Wnt5a suppressive properties detected in tumours connoted by β-catenin hyper-activation 369 
has been linked to the shift towards the stimulation of the β-catenin independent signalling pathway. 370 
Foxy5 is a Wnt5a mimicking hexapeptide able to decrease BC cell migration and invasion [74]. 371 
More recently Prasad et al. [75] confirmed these data and added new information on the role of Wnt5a 372 
in the regulation of the expression of the phosphofructokinase platelet-type (PFKP). They have shown 373 
that low PFKP level correlates to cancer cell migration and poor patients’ survival. The growth and 374 
expansion of tumour cells also rely on glucose consumption resulting in the accumulation of lactate. 375 
Cancer cell metabolism was also associated with β-catenin activation [76]. At this regard, it has been 376 
shown that Wnt5a affects the aerobic glycolysis by inhibiting the activation of β-catenin. Therefore, 377 
an onco-suppressive role was proposed for PFKP. 378 
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According to the study of Borcherding et al. [77], Serra Roarty et al. [76][78] demonstrated that 379 
the paracrine activity of Wnt5a suppresses the expression of both β-catenin and cyclin D1. The authors 380 
have shown that Wnt5a supports TGF-β-mediated tumour suppressive functions by antagonising 381 
Wnt/β-catenin signalling and limiting tumour cell proliferation. 382 
Moreover, Leris and colleagues [79] proved that Wnt5a mRNA level was significantly lower in 383 
tumour than in normal tissues, particularly in those displaying a more aggressive behaviour. Again, 384 
this observation has suggested a suppressive role of Wnt5a in cancers. It has been also reported that 385 
loss of Wnt5a associates with a higher histological tumour grade, increased risk of recurrence, and a 386 
shorter recurrence-free survival in invasive BC [80] (Table 1). 387 
On the contrary, Kobayashi et al. [81] reported that Wnt5a is expressed in ER-positive BC cells 388 
and positively associates to vessel invasion, tumour size and migration. Mechanistically, Wnt5a 389 
induces the expression of the activated leukocyte cell adhesion molecule (ALCAM), a protein 390 
involved in migration and invasion. Knockdown of either Wnt5a or ALCAM inhibited tumour cell 391 
migration, confirming the role of the Wnt5a/ALCAM axis in the migratory phenotype of ER-positive 392 
BC (Table 1). 393 
A relevant role of Wnt5a in reprogramming the TME was also described [82]. It has been shown 394 
that under pro-inflammatory conditions the non-canonical Wnt protein induces the expansion of the 395 
CD163(+) immunosuppressive macrophages translating in the release of IL-10 and the inhibition of 396 
the classical TLR4-NF-kB signalling pathway [82]. 397 
Moreover, higher level of Wnt5a was found in human monocyte-derived myeloid dendritic cells 398 
(Mo-mDCs) than in normal monocytes and macrophages. Wnt5a was found to inhibit the generation 399 
of Mo-mDCs by stimulating BC cells to produce IL-6. In addition, the presence of IL-6 in the 400 
conditioned media of Wnt5a stimulated BC cells was found involved in the inhibition of Mo-mDC 401 
differentiation [83]. Consistently, overexpression of Wnt5a mRNA was detected in metastases 402 
derived from primary BC cells and in BC cell lines [84]. 403 
Wnt5a signalling is also able to modify the CD44-AKT signalling pathway, leading to a reduced 404 
BC cell migration and invasion. In epithelial BC cells, silencing of Wnt5a drives EMT-like changes 405 
without altering the expression of common EMT markers. On the contrary, it interferes with CD44 406 
expression and induces pAKT downregulation, thereby acting via a EMT-independent mechanism 407 
[85].  408 
The dual activity of Wnt5a has been also ascribed to the Wnt5a isoforms. Bauer et al. [86] have 409 
shown that the Wnt5a gene encodes for two distinct isoforms: the Wnt5a-long (Wnt5a-L) and Wnt5a-410 
short (Wnt5a-S) isoform. When analysed in several cell lines Wnt5a-L reduced tumour progression, 411 
while Wnt5a-S promoted tumour growth.  412 
Overall, Wnt5a may play multiple roles. Whether it acts as a tumour suppressor or a tumour 413 
promoter remains elusive and depends on the availability of essential receptors, the TME, and the 414 
activation of discrete signalling pathways. 415 
TRIPLE-NEGATIVE BREAST CANCER 416 
Triple-Negative Breast Cancer (TNBC) is an invasive type of breast carcinoma that lacks the 417 
expression of estrogen and progesteron receptor as well of the human epidermal growth factor 418 
receptor 2 (HER2) [87] and accounts from 10 to 15% of all BC [88]. 419 
TNBC patients have poor outcome due to the high grade of proliferation, early tumour 420 
dissemination, and the lack of targeting approaches [89,90]. The malignancy is associated with earlier 421 
age of onset, aggressive clinical course, and dismal prognosis [88]. TNBC gained attention due to the 422 
aggressiveness and the lack of effective treatment options. Therefore, the most relevant data on this 423 
breast cancer subtype are independently discussed. 424 
Gene expression omnibus (GEO) databases were applied by Shen et al. [91] to gather gene 425 
expression data in TNBC patients who underwent chemotherapy. They reported that co-expression 426 
of NIMA-related kinase 2 (Nek2) and β-catenin correlated with patients’ poor prognosis. β-catenin 427 
binds to and is phosphorylates by the Nek2B isomer. Thereby, in TNBC, Nek2B functions as a β-428 
catenin regulator by activating the Wnt signalling pathway and its downstream target genes. In 429 
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addition, it has been suggested that Nek2B and β-catenin may synergize to promote resistance to 430 
chemotherapy. However, further studies are required to better elucidate the relationship between β-431 
catenin and Nek2 and its possible implications in cancer development (Table 1). 432 
TNBC aggressiveness also relies on the activation of the non-canonical Wnt/PCP pathway. 433 
Indeed, the aberrant activation of downstream genes activated by the non-canonical Wnt/PCP 434 
pathway has been implicated in tumour growth and poor prognosis. Results from Puvirajesinghe 435 
and colleagues [92] revealed that van gogh-like 2 (VANGL2), a core Wnt/PCP component, plays a 436 
crucial role in cancer cell migration, anchorage-dependent and independent cell proliferation, as well 437 
as in tumour growth. Since, the scaffold p62/SQSTM1 protein, a VANGL2-binding partner, has a key 438 
role in VANGL2–p62/SQSTM1–JNK pathway, the possibility to exploit p62/SQSTM1 as a potential 439 
therapeutic target has been proposed. This would be of particular relevance since the JNK targeting 440 
approaches are associated with major side effects in clinical setting (Table 1). 441 
Yu and colleagues [93] demonstrated that the hematopoietic protein tyrosine phosphatase 442 
(HePTP) stabilizes β-catenin in the cytoplasm and allows its nuclear translocation by regulating the 443 
phosphorylation of GSK-3β. This results in the transcriptional activation of target genes leading to 444 
cell migration and invasion. Since knockdown of HePTP significantly suppresses metastases formed 445 
by TNBC cells, HePTP has been also proposed for therapeutic approaches in TNBC (Table 1). 446 
Recently, Kong et al. [94] have shown that a Rho-GTPase-activating protein, the deleted in liver 447 
cancer gene 3 (DLC-3), is downregulated in TNBC and its expression is linked to lymphatic 448 
metastases. DLC-3 overexpression leads to β-catenin and c-myc downregulation as well as in reduced 449 
in vitro cell proliferation, colony formation, migration, and invasion. Hence, a tumour-suppressor 450 
role related to the inhibition of the Wnt/β-catenin signalling pathway has been postulated (Table 1). 451 
Liu and colleagues [95] have reported a low expression of miR-6838-5p in TNBC compared to 452 
normal cells. miR‐6838‐5p overexpression reduced cell invasion, migration, EMT, β‐catenin, c‐myc 453 
and cyclin D1 expression by post-transcriptionally controlling Wnt3a expression. 454 
Recently, miR-27a-3p was found overexpressed in tumour cells and linked to poor prognosis in 455 
TNBC patients. miR-27a-3p leads to the activation of Wnt/β-catenin cascade and enhances cell 456 
proliferation and migration by directly targeting the 3ʹ-UTR region of GSK-3β [96] (Table 2).  457 
OVARIAN CANCER  458 
Ovarian Cancer (OC) is a global issue representing the fourth most common cancer in the female 459 
population, particularly in developed countries [97]. The poor survival rate is mainly due to the lack 460 
of screening methods at the early stages along with the absence of effective treatment options for 461 
advanced stages [96][98]. Among different OC subtypes, the epithelial subtype (EOC) holds about 462 
90% of the overall ovarian malignancies [97][99].  463 
Canonical Wnt pathway and OC 464 
Wnt/β-catenin signalling pathway play a crucial role in carcinogenesis of all OC subtypes 465 
[98][100]. In particular, several transcription factors, proteins and miRNAs acting on this pathway 466 
have been explored [99][101]. 467 
Chen and co-workers [102] investigated the role of the Wnt/β-catenin pathway antagonist 468 
dickkopf-related protein 1 (DKK1). They showed that DKK1 is involved in the control of OC stemness. 469 
Mechanistically, it has been shown that STAT3 directly activates the transcription of miRNA-92a, 470 
translating in DKK1 downregulation [102]. Moreover, overexpression of miR-1207 was found to 471 
correlate with high nuclear β-catenin level [103]. Wu et al. [103] investigated the effects of miR-1207 472 
on the expression of the SFRP1-AXIN2 and the inhibitor of β-catenin and T cell factor 4 (ICAT). They 473 
found that miR-1207 overexpression was associated with a reduced SFRP1-AXIN2 and ICAT 474 
expression and the appearance of a stem-like phenotype (Table 1).  475 
Salem et al. [104] proved that miR-590-3p promotes OC growth and metastasis, by targeting 476 
FOXA2. Moreover, it has been shown that miR-590-3p upregulation significantly increase cell 477 
growth, migration, and invasion in EOC cells, both in vitro and in vivo [105]. Similarly, FOXA2, which 478 
exhibits suppressive activity on EOC cells, has been identified as a miR-590-3p target [105]. The cyclin 479 
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G2 gene (CCNG2) has been also reported to display several repressive actions on EOC-derived 480 
tumour cell lines. It inhibits cell proliferation, migration, invasion and EMT. Thereby, since miR-590-481 
3p post-transcriptionally regulates FOXA2, FOXO3, CCNG2 and DDK1 expression, miR-590-3p has 482 
been proposed as a potential target in EOC patients [105]. A crucial role of SFRP1 in OC growth has 483 
been also proposed. Since miR-1180 is highly expressed in neoplastic tissues, Hu et al. [106] explored 484 
the relationship between miR-1180 and the SFRP1/Wnt/β-catenin signalling pathway in this context, 485 
demonstrating that miR-1180 triggers the activation of the Wnt/β-catenin cascade by targeting SFRP1.  486 
The members of the R-spondin ligand family have been reported as positive effectors of the 487 
Wnt/β-catenin signalling [107]. LGR4-6 plays crucial roles in the activation of the Wnt/β-catenin 488 
cascade [107,108]. Moreover, Ruan et al. [107] have reported that LGR6 induces stemness and chemo 489 
resistance via the Wnt/β-catenin pathway in OC cells. Restrain of the stem phenotype and increased 490 
sensitivity to chemotherapy have been proved by LGR6 silencing (Table 1). 491 
A recent study established that the overexpression of the Rab GTPase family member, Rab14, 492 
regulates GSK-3β phosphorylation and β-catenin nuclear accumulation [109,110]. Moreover, high 493 
level of Rab14 was found associated with higher expression of Wnt/β-catenin target genes including 494 
MMP-7 and c-myc [110](Table 1). 495 
Jiang et al. [97] have demonstrated that tetrandrine (TET) enhances the anti-tumour effect of 496 
paclitaxel (PTX) by decreasing c-myc and cyclin D1 and increasing p21 expression, resulting in cell 497 
cycle arrest. The pro-apoptotic effects of PTX+TET have been also investigated. TET was found to 498 
inhibit β-catenin downstream target genes by enhancing PTX activity and conferring sensitivity to 499 
PTX in resistant cells [97].  500 
Barghout and co-workers [111] demonstrated a more active Wnt/β-catenin signalling in 501 
carboplatin-resistant cells than in sensitive ones. Unlike the Wnt ligands, the negative Wnt regulators 502 
DKK1, SFRP1, and the FRZB have been found downregulated in cisplatin-resistant cells. These 503 
findings suggest that Wnt/β-catenin blockade may be effective on resistant EOC. 504 
Non-canonical Wnt pathway and OC 505 
The FZD7 is highly expressed in OC [112] and its overexpression in mesenchymal (Mes) and 506 
Stem-A OC subtypes, has been associated with the induction of EMT. The PCP pathway, which 507 
activates the Rho-ROCK axis, was found involved in the activation of actomyosin contractility, 508 
cadherin-based cell-cell adhesion and migration, while the Wnt/calcium pathway in the metastatic 509 
spread and cytoskeleton changes in this clinical setting [112]. Therefore, it has been proposed that the 510 
FZD7 controls both cell cycle progression and cell migration via the non-canonical Wnt/PCP pathway 511 
(Table 1). 512 
The integrin beta like 1 subunit (ITGBL1) was found highly overexpressed in OC [113]. It has 513 
been shown that ITGBL1 promotes cell migration and adhesion via Wnt/PCP, RhoA, the focal 514 
adhesion kinase, and the steroid receptor coactivator (FAK/src) pathway (Table 1). 515 
The PTK7 which interacts with Wnt5A, LRP6 and FZD7 [114,115] may act as tumour suppressor 516 
or oncogene [116,117]. In EOC, PTK7 downregulation is indeed associated with a poor prognosis 517 
[116]. 518 
Luo and colleagues [118] have investigated the role of the alkaline phosphatase (ALPL) in OC. 519 
They demonstrated that ALPL overexpression inhibits EMT, migration and invasion of high grade 520 
serous OCs (HGSOC) and FZD2 correlates with a poor survival rate [118]. Mechanistically they have 521 
shown that ALPL overexpression represses Wnt5a/FZD2–mediated EMT activation possibly by 522 
interfering with STAT3 activation [118] (Table 1). 523 
WNT PATHWAY AND OTHER CANCERS 524 
Glioma is an aggressive tumour of the nervous system displaying rapid progression and poor 525 
prognosis. Zhao et al. [119] have found that overexpression of β-catenin and cyclin D1 is associated 526 
with high level of the long noncoding RNA, FGD5 antisense RNA 1 (lncRNA FGD5-AS1). A close 527 
relationship between them was straitened by the observations that inhibition of FGD5-AS1 reduced 528 
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β-catenin and cyclin D1 expression while β-catenin downregulation decrease lncRNA FGD5-AS1 529 
expression. This results in the impaired tumour cell migration and invasion. 530 
Prostate cancer (PCa) is among the most common tumour in male. A recent study by Situ et al. 531 
[120] provided evidence for the involvement of the microRNA-939 (miR-939) in PCa. Downregulation 532 
of miR-939 was found in tumour tissues at advanced tumour stage, in distant lesions as well as 533 
associated with poor prognosis. Molecularly, it was demonstrated that miR-939 upregulation 534 
interferes with the Wnt/β-catenin cascade by directly targeting the hepatoma-derived growth factor 535 
(HDGF). 536 
Osteosarcoma (OS) is a common bone paediatric tumour displaying high rate of lung metastasis. 537 
The inhibition of β-catenin activation, metastasis formation and chemo-resistance were found 538 
modulated by tegavivint (a Wnt/β-catenin inhibitor) which has been proposed as an alternative 539 
therapeutic option in OS [121]. 540 
Melanoma is among the most immunogenic tumours displaying increased lymphocytic 541 
infiltration. Low 1α,25-dihydroxyvitamin D3 and vitamin D receptor (VDR) level correlates to 542 
increased cancer incidence and melanoma progression, respectively. Recently, it has been shown that 543 
high VDR expression correlated with the inhibition of tumour growth, low Wnt/β-catenin activation 544 
and the induction of the immune response [122] (Table 1). 545 
The long non-coding RNA00261 (Linc00261) has been shown to display onco-suppressor 546 
properties in Pancreatic Cancer (PC). Linc00261 overexpression inhibits PC cell proliferation, 547 
invasion, EMT and metastasis. Bioinformatics analysis revealed that Linc0026 inhibits the activation 548 
of the β-catenin/TCF4 cascade and the metastatic spread by regulating the miR-552 5p/FOXO3 axis 549 
[123]. 550 
 551 
EXTRACELLULAR VESICLES AND THE WNT PATHWAY  552 
EVs are heterogeneous small membrane-bound carriers with complex cargoes released under 553 
both physiological and pathological conditions. Almost any cell can release EVs, which act as inter-554 
cellular mediators modifying target cell fate at closed or distant sites [121][124]. 555 
Based on the biogenesis, size, content, mechanisms of release and function, three discrete EV 556 
subtypes are recognized: microvesicles (MVs), exosomes, and apoptotic bodies [121][124].  557 
EVs-mediated transfer of specific molecules are known to dictate the phenotype of the recipient 558 
cell. They can act on proliferation, motility, EMT, migration, invasion, immune evasion, chemo-559 
resistance, and TME reprogramming (Figure 3). 560 
 561 
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Figure 3. Schematic representation of cell-to-cell communication in the TME by EVs. EVs are 562 
released by almost all cell types in the TME. EVs serve as inter-cellular mediators transferring specific 563 
molecules (proteins including Wnt ligands and β-catenin, and miRNAs) to recipient cell thus 564 
promoting tumour expansion, cancer cell dedifferentiation in CSCs, chemo-resistance, and neovessel 565 
formation. CCs: cancer cells; CSCs: cancer stem cells; TEC: tumour-derived endothelial cell; CAF: 566 
cancer associated fibroblasts. 567 
Moreover, EVs derived from serum or other biological fluids have been proposed as tumour 568 
biomarkers. More importantly, EVs have gained attention as anti-cancer tools. Indeed, EVs can be 569 
used as drug delivery systems or potential cancer vaccines. Moreover, the transfer of Wnt ligands or 570 
β-catenin via EVs has been proposed as a Wnt signalling activation mechanism. 571 
Kalra et al. [125] have shown that EVs released by CRC cells and containing the mutant β-catenin 572 
and high Wnt/β-catenin activity boost the expression of target genes as c-myc and cyclin D1 when 573 
transferred to recipient cell (Table 13).  574 
 575 
Table 3. EVs involved in several tumours, their alteration, targets, and impact on tumours 576 















































































The 14-3-3 are conserved molecules displaying regulatory functions and promoting cancer 578 
progression [126]. The 14-3-3ζ isoform which binds both β-catenin and GSK-3β, leads to the nuclear 579 
translocation and accumulation of β-catenin and enhance cell motility. Moreover, EVs enriched in 14-580 
3-3ζ and β-catenin, after internalization, promote cell survival and migration by activating the Wnt/β-581 
catenin cascade [126] (Table 13). 582 
Hu et al. [127] have investigated the mechanism of drug resistance in CRC and have proven that 583 
EVs released by fibroblasts drive dedifferentiation of CRC cells towards CSCs (Figure 3a). 584 
Additionally, they found that EVs derived from fibroblasts contain the Wnt ligands which activate 585 
the Wnt/β-catenin pathway in target cells, induce transdifferentiation of CRC cells into CSCs and 586 
increase drug resistance. Furthermore, it has been reported that collagen accumulation and the APC 587 
mutation in CRC cells stimulate the release of EVs and, under hypoxia conditions, fibroblast derived 588 
EVs boost CRC colony formation [128] (Table 13). 589 
Accumulating evidence shows that EVs enriched in miRNAs are key determinants of human 590 
cancer cell growth, invasion and metastasis [129][129]. CAF-derived EVs enclose miR-92a-3p which 591 
contribute to cancer progression, stemness, EMT, and drug resistance. Moreover, miR-92a-3p 592 
enriched EVs correlated with the activation of the Wnt/β-catenin pathway [129] (Figure 3a). 593 
Long non-coding RNA-APC1 (lncRNA-APC1) is a negative regulator of CRC. Low level of 594 
lncRNA-APC1 correlates with metastasis, advanced clinical stage and poor prognosis in CRC 595 
patients. APC, via lncRNA-APC1 promotes cell-cycle arrest and suppresses angiogenesis by lowering 596 
the release of CRC cell-derived EVs. Finally, it has been shown that EV-derived from CRC are 597 
enriched in Wnt1 and enhance CRC cell proliferation and migration via the non-canonical Wnt/PCP 598 
signalling [130]. 599 
Hepatocellular carcinoma (HCC) is one of the most common cause of cancer-related deaths 600 
worldwide. Constitutive activation of the Wnt/β-catenin pathway turns into the expression of the 601 
epithelial cell adhesion molecule (EpCAM) [131]. Ishiguro et al. [132] provided evidence that loss in 602 
β-catenin and reduced proliferation and invasion can be obtained by EpCAM positive liver cancer 603 
stem cells (LCSC) targeted by EVs engineered with a β-catenin specific siRNA (Table 13). 604 
Multiple myeloma (MM) is a hematopoietic malignancy associated with an altered homeostasis 605 
of bone formation/resorption. MM-derived EVs enriched in DKK-1 were found to boost the Wnt/β-606 
catenin signalling and contribute to the abnormal osteogenesis. The inhibition of EV shedding 607 
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combined to chemotherapy were found to impair tumour load, angiogenesis and osteolysis [133] 608 
(Table 13). 609 
Furthermore, a recent study noticed that the release of EVs from HCC cells is increased in 610 
hypoxic conditions and linked to cancer cell proliferation, migration, invasiveness and EMT. 611 
Mechanistically they have shown that miR-1273f enriched in EVs activates the Wnt/β-catenin 612 
signalling cascade by targeting the Wnt/β-catenin inhibitor LHX6 [134]. 613 
Chen et al. [135] proved that EVs released from oral squamous cell carcinoma (OSCC) cells 614 
correlate with the increased level of β-catenin, the expression of several oncogenic markers, the 615 
reprogramming of normal gingival fibroblasts into CAFs, the increased metastasis, stemness 616 
reprogramming, chemoresistance, and patients’ poor survival (Table 13).  617 
Xia et al. [136] have demonstrated the uptake of EVs and the delivery of functional miRNAs in 618 
different cell lines. The exosomal-miR-1260b was found crucial for the activation of the Wnt/β-catenin 619 
signalling and the invasivness of lung adenocarcinoma cells. 620 
Harada et al. [137] purified and characterized Wnt5b-associated EVs. In pancreatic PANC-1 and 621 
colorectal Caco-2 cell lines Wnt5a carried by EVs displays the ability to enhance cancer progression 622 
(Table 13). 623 
Luga et al. [138] demonstrated that EV shedding by fibroblasts boosts BC cell growth and 624 
motility via the Wnt/PCP signalling. CAF-derived EVs were found crucial drivers of cell migration 625 
during metastasis formation. Moreover, they found that EVs secreted from fibroblast L cells promote 626 
the autocrine Wnt11-PCP cascade in tumour cells increasing their motility and metastatic properties 627 
(Table 13). 628 
Lombardo et al. [139] provided evidence that EVs released by tumour-derived endothelial cells 629 
(TECs-EVs) boost in vivo TEC-derived neovessels. Mechanistically they showed that EV released by 630 
naive TECs-EVs regulate the expression of APC, GSK-3β and drive β-catenin nuclear accumulation 631 
via miR-214-3p and miR-24-3p (Figure 3b). Overall, this study revealed a key role of the Wnt/β-632 
catenin cascade in TEC-derived neovessel formation. Moreover, they recently showed that naïve 633 
TEC-EVs were also able to boost TNBC metastatic spread and lung metastasis formation when 634 
injected intravenously [140] (Table 2). 635 
Overall these data indicate a crucial contribute of EVs released by different cell sources in 636 
driving tumor development and dissemination. Several data suggest that these effects mainly rely on 637 
the transfer of their specific cargo into target cells. Therefore, approaches able to modify their cargo, 638 
particularly miRs and proteins involved in their tumor promoting action, have been proposed as 639 
useful therapeutic options. EV engineering by using siRNA for mutated protein has been tested and 640 
their effectiveness demonstrated in pancreatic cancer [141]. This suggests that using siRNA for 641 
mutant β catenin should be considered as an alternative option for CRC. Likewise, siRNA for 642 
different Wnt proteins or rearrangement of dysregulated EV miRs can be used to targeting the Wnt/β 643 
catenin cascade. Alternatively, EVs loaded with Wnt/β catenin inhibitors can be used as naturally 644 
delivery tools. 645 
CONCLUSIONS 646 
Cell-to cell communication is part of the evolutional processes. Wnt ligands are essential for the 647 
homeostasis and in the last 30 years genetic, biochemical, and molecular investigations have 648 
uncovered several Wnt signalling components [2,3]. Driving interest on this topic mainly relies on 649 
dysregulation of the Wnt/β-catenin signalling and cancer development/progression [3]. Moreover, 650 
Wnt/β-catenin cascade seems to contribute to the TME shape, which play a crucial role in the control 651 
of tumour progression and immune regulation. Many different Wnt proteins have been described, 652 
and among them Wnt5a, plays a critical role taking part in both the canonical and the non-canonical 653 
Wnt/β-catenin pathway [77,78]. 654 
The identification of specific tools able to interfere with the Wnt/β-catenin cascade has been a 655 
hotspot for many years. This is particularly true for CRC, in which almost 70% of CRC patients 656 
display APC mutations [15]. Apart from CRC, the Wnt/β-catenin pathway is gaining attention in 657 
several malignancies, such as breast, ovarian, melanoma, prostate and paediatric osteosarcoma [117–658 
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119]. At this regard, BC and in particular TNBC are featured by the abnormal activation of both the 659 
canonical and non-canonical Wnt/β-catenin pathway [89,90]. Likewise, a hyper-active Wnt/β-catenin 660 
cascade has been shown to play a crucial role in the progression, stemness, and drug resistance in OC 661 
[101,105]. Several miRNAs have been identified to modulate this cascade and thereby widely studied 662 
as screening markers or targets in different tumour settings [142]. 663 
In the TME, intercellular communication has been recently reported as mediated by the transfer 664 
of EV molecular cargo and revised in [143]. Their cargo also includes a number of Wnt components. 665 
Of note, wild-type and mutant β-catenin able to promote survival and proliferation of recipient cell 666 
and, in several instance dedifferentiation towards a CSC phenotype, have been detected in EVs 667 
(Figure 3a). Moreover, their role in mediating drug resistance has been reported. Furthermore, since 668 
EVs are released within the TME their contribute in cancer growth and progression has been 669 
extensively investigated [144]. EV shedding, blockade, or engineering have been proposed as 670 
innovative anti-tumour instrument to fine-tuning the Wnt/β catenin pathway [142,145].  671 
In the last decades several efforts have been directed to the development of Wnt/β catenin 672 
targeting approaches in order to interfere with tumour progression. However, these efforts have been 673 
limited by the crucial role of the Wnt/β catenin pathway in preserving tissue homeostasis. Therefore, 674 
future energies should be directed to clearly dissect the mechanisms driving the unbalanced Wnt/β 675 
catenin pathway in cancer, and EV mechanism of action should be considered amid them. Should 676 
identified, targeting approaches would become a suitable anti-cancer option.  677 
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